Ticagrelor is an oral antiplatelet medication used to inhibit blood clots in patients with acute coronary syndromes or a history of myocardial infarction. It is commonly used along with aspirin to prevent heart attacks and strokes in high-risk patients. Ticagrelor works by reversibly binding to the P2Y12 receptor on platelets, reducing platelet aggregation and thrombus formation. The growing prevalence of cardiovascular diseases has increased the demand for antiplatelet drugs like ticagrelor for treatment and prevention of conditions like myocardial infarction and unstable angina.

The Global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the ticagrelor market are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG, Standard Industries Inc., and The Dow Chemical Company. These key players are actively focusing on new product developments and geographic expansion to strengthen their presence in the global market. Key opportunities in the ticagrelor market include increasing healthcare spending in emerging economies, improving accessibility of healthcare facilities, rise in approval of new drugs for cardiovascular disorders, and growing geriatric population which is at high risk of cardiovascular diseases. The market players are also exploring opportunities in developing regions like Asia Pacific and Latin America through joint ventures and collaborations with local players.

Atals Roofing Corporation recently expanded its operations in China and India to cater to the burgeoning demand for Ticagrelor Market Size in these lucrative markets. Similarly, BASF SE inaugurated a new production facility in Brazil to capitalize on the opportunities arising due to growing cardio-metabolic disorders in Latin America. These global expansion strategies are anticipated to drive the overall ticagrelor market during the forecast period. Market drivers One of the key drivers of the ticagrelor market is the rising prevalence of cardiovascular diseases worldwide. As per the WHO, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. Moreover, increasing adoption of unhealthy lifestyles and growing geriatric population are further contributing to the increasing incidence of myocardial infarction, unstable angina and other cardiac conditions. Since ticagrelor is one of the preferred antiplatelet drugs for managing these conditions, its demand is growing steadily each year. Market restrain Stringent regulations pertaining to drug approval and high costs associated with clinical trials are some of the key factors restraining the growth of ticagrelor market. New drug candidates need to undergo rigorous testing to demonstrate efficacy and safety. Moreover, lengthy approval timelines and high investment requirements pose significant challenges for market players, especially smaller companies and startup firms. Regulatory uncertainty also inhibits market expansion to some extent. Addressing these regulatory challenges would be important for sustained growth of the Ticagrelor Market Size and Trends over the coming years.

Segment Analysis The global ticagrelor market is segmented based on the application, distribution channels and region. Based on application, the market is segmented into acute coronary syndrome, unstable angina pectoris and others. Among these, the acute coronary syndrome dominates the market and accounts for the major share owing to rapidly growing cases of heart attacks every year and preference ticagrelor over other alternatives. Based on distribution channels, the ticagrelor market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies hold the prominent share in the market due to increasing prescription of ticagrelor by cardio specialists for ACS patients. Regional Analysis North America holds the major share in the ticagrelor market due to rise in preference for personalized medicines over traditional approaches and presence of developed healthcare infrastructure and reimbursement policies. Europe is the second largest regional market supported by growing awareness about advantages of ticagrelor over other drugs. Asia Pacific shows fastest growth owing to rapidly increasing geriatric population susceptible to cardiovascular diseases, improving access to healthcare facilities and rise in healthcare spending.

Get More Insights On, Ticagrelor Market

Long-term use of AZ’ Brilinta, ticagrelor gets US priority review

  An application to use AstraZeneca’s Brilinta to treat patients with a history of heart attack has been placed on a fast track regulatory pathway in the US, meaning that approval could be granted within just six months.

 http://www.pharmatimes.com/Article/15-04-29/Long-term_use_of_AZ_Brilinta_gets_US_priority_review.aspx

The US Food and Drug Administration has assigned a priority review based…